HIMS Hims & Hers Health, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
10:23
Jun 03
Jun 03
The author lists favorite stocks by sector as a thematic watchlist without explicitly stating current positions or forward calls, so each ticker is indexed as watch.
LOW
10:18
Jun 03
Jun 03
The author lists favorite stocks per sector as a thematic watchlist without explicitly stating current positions or forward calls, so all tickers are indexed as watch.
LOW
02:33
Jun 03
Jun 03
The tweet is a casual lifestyle post listing recent events and vague bullish-sounding phrases about AMD, HIMS, and PLTR without any explicit position, catalyst, or forward-looking trade thesis.
LOW
18:46
Jun 02
Jun 02
Author remains long PALU through earnings, citing strong buyer activity and a fundamental shift in cybersecurity demand due to Mythos, while acknowledging the high implied move and his mixed earnings record.
14:24
Jun 02
Jun 02
The author admits HIMS was a bad trade cut at a loss, but this is a past-tense reflection, not a current position or forward call.
LOW
14:15
Jun 02
Jun 02
The author shares past positions and losses across several tickers but provides no forward-looking directional view or current conviction, making these watch-only mentions.
LOW
10:39
Jun 02
Jun 02
The author outlines a hypothetical long-term portfolio of nine names built for asymmetric upside, implying a bullish conviction on each ticker as core holdings.
12:06
Jun 01
Jun 01
Author names HIMS alongside OUST as a candidate for 1,000%+ upside in 12-24 months in direct response to a "next big bets" question, implying high-conviction multi-bagger potential.
MED
18:16
May 31
May 31
The author jokingly asks for a return of a past trading challenge involving HIMS, not a current position or forward catalyst.
LOW
11:06
May 30
May 30
The author exited NBIS calls and suggests keeping some HIMS for peptide exposure but prefers AI plays, offering a personal allocation opinion rather than a definitive trade call.
LOW
08:04
May 30
May 30
The author reflects on past investing trends and personal style focused on chokepoints, but does not state any current positions or forward calls.
LOW
15:13
May 28
May 28
The author reflects on a past losing trade in Hims but does not express a current forward-looking view or position.
LOW
13:45
May 28
May 28
Lead Independent Director David Wells made a discretionary open-market purchase of 48,400 HIMS shares (~$1.17M) per SEC filing.
MED
12:49
May 27
May 27
Hims & Hers Health Board Member Wells made a discretionary purchase of approximately $1.2M in HIMS shares.
MED
22:11
May 26
May 26
Author flags first insider purchase at HIMS in years — named insider buying event, a fundamental signal worth monitoring.
MED
18:28
May 26
May 26
The author boasts an 87.7% return on $10K across multiple public buy calls, reinforcing a bullish outlook on OUST, MRVL, POET, HIMS, WOLF, and FLNC by highlighting their gains.
00:00
May 26
May 26
Bought 48,400 shares @ $24.23
Open market purchase: 48,400 shares at $24.23 ($1,172,974 total)
HIGH
21:08
May 25
May 25
The tweet simply lists retail favorite stocks without expressing any forward-looking opinion or directional view on their performance.
LOW
17:37
May 25
May 25
The tweet humorously compares the price race between oil and HIMS stock to reach $100, but lacks a clear directional view or trade recommendation.
LOW
14:00
May 25
May 25
Long Hims on baldness cure
If a cure for male pattern baldness is discovered by a private company, Hims will benefit as a distributor, signing deals with the patent holder.
HIGH
01:46
May 25
May 25
The tweet reports on Hims & Hers CEO's strategic plans to disrupt healthcare but does not express a forward-looking view on the stock.
LOW
12:45
May 24
May 24
Author increased their position in HIMS despite it being the worst laggard at -34.61%, indicating a contrarian bet on a rebound or continued conviction in the thesis.
HIGH
19:32
May 23
May 23
The author recaps past trades on HIMS, UUUU, USAR, BTC, and BB with price entries and outcomes but expresses no forward-looking opinion or new trade thesis.
HIGH
02:19
May 23
May 23
Long Hims on baldness cure
A cure for male pattern baldness would be a massive blockbuster drug. Hims, as a telehealth and distribution platform, would likely sign a partnership and see its stock soar.
LOW
22:39
May 22
May 22
Baldness cure, long HIMS
If a cure for male pattern baldness is invented, long Hims & Hers (HIMS) because they will distribute the drug and the stock will candle green.
MED
12:41
May 22
May 22
Hims weak fundamentals avoid.
Hims & Hers has very volatile and weak fundamentals. Gross margin dropped from 80% to 57% due to regulatory issues and product mix. He advises staying away completely.
MED
18:57
May 19
May 19
Peptides catalyst around July FDA meeting + only telehealth player with peptide facility; Labs data moat unmatched. 2026 driven by peptide news.
HIGH
17:11
May 19
May 19
Top 3 stock pick for 2026, at a great price right now despite -33% YTD.
HIGH
13:56
May 17
May 17
The author criticizes non-technical AI experts for misusing buzzwords and conflating unrelated technologies, dismissing their commentary on photonics, CXL memory pooling, and specific tickers like $PENG and $TSEM as uninformed.
HIGH
12:45
May 17
May 17
HIMS is the largest laggard but remains a position in the conviction-driven portfolio; the author is not trading around short-term volatility.
MED
About HIMS Analyst Coverage
Buzzberg tracks HIMS (Hims & Hers Health, Inc.) across 35 sources. 174 bullish vs 8 bearish calls from 49 analysts. Sentiment: predominantly bullish (63%). 262 total trade ideas tracked.